Congratulations to Dr. Amédée Renand, whose project has been selected for the 2025 AFEF award!

Rencontre / Echanges : Sclérose en plaques, où en est la recherche?

Sepsis induces immune changes that persist for months after the disease has resolved. Read the results of our study published in Nature Immunology and discover how sepsis survivors had a lower cumulative incidence of cancer and how a chemokine network released by sepsis-resident macrophages promotes tissue-resident T cells. PMID: 38684922

Team 3 Integrative Transplantation, HLA, Immunology, and Genomics of Kidney Injury (iTHINK) at CR2TI UMR1064 INSERM, Nantes Université, will host an international symposium on Immunoinformatics on May 24, 2024. The symposium will bring together over 80 researchers and specialists in the field at the MSH Ange Guépin, Nantes.

Questions about the BEST-Fluid Trial? Christophe Masset, Lucile Figueres and colleagues at ITUN and CR2TI are in correspondence in The Lancet with the authors of the clinical study and the use of balanced crystalloid solutions to prevent kidney damage (DGF) after transplantation. Although the results are promising, more research is needed to confirm their efficacy, especially in light of new organ preservation techniques such as machine perfusion. To further reduce DGF, several factors have been identified: minimizing organ damage during surgery, using advanced preservation methods, optimizing anti-rejection medications, and potentially using new treatments for both donors and organs.

A new approach to treating acute liver failure. Researchers from CR2TI UMR 1064 Nantes with colleagues from GoLiver Therapeutics created frozen, immature liver cells derived from stem cells (GStemHep). In mice with liver failure, a single dose of thawed GStemHep cells improved liver function rapidly, even without immune system suppression. These cells seem to work by reducing inflammation and stimulating the recipient's own liver cells to regenerate. This is a promising new direction for liver disease treatment

The study published in JAMA Neurol by David Laplaud and colleagues from CR2TI UMR 1064 Nantes and #OFSEP investigated the effectiveness of different treatments for pediatric multiple sclerosis (POMS). They found that using highly effective therapies (HETs) as the first treatment resulted in Reduced relapses, Less MRI activity and Better tolerability. These findings suggest that HETs might be a better first-line treatment for POMS, although long-term safety studies are still needed.

Respiratory microbial dysbiosis is associated with acute respiratory distress syndrome (ARDS) and hospital-acquired pneumonia (HAP) in critically ill patients. Read the results of the validated robust respiratory microbiome signatures associated with ARDS and HAP, published in Nature Med. Such signatures may help to identify promising targets for microbiome therapeutic modulation in critically ill patient. PMID: 37957375

Whether interferon gamma-1b prevents hospital-acquired pneumonia in mechanically ventilated patients ? Read the results from the randomized clinical trial published in Intensive care med

Nicot A. et al. identified the e1 sequence of KIR4.1 as an autoantigen of interest in selected group of patients suffering from Multiple Sclerosis. Congratulations to the NEMO_Team of the CR2TI for their paper in Brain Communications.

Découverte d'une signature spécifique du microbiote oral dans la sclérose en plaques Conçu par Léo Boussamet (doctorant), Laureline Berthelot (chercheure) et Arnaud Nicot (chercheur) et dessinée à la craie avec Pierre-Olivier Bertho, Emilie Dugast, Alexandra Garcia, Emeline Gauthier, Louise Le Gal et Sita Shah

BioMAdvanced Diagnostics created by Dr S brouard and Dr R Danger, a new spinn off from the CR2TI